Cargando…

Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy

In relapsed and refractory multiple myeloma (MM), adoptive cell therapies (ACT) including CAR-T-cells are under clinical investigation. However, relapse due to T-cell exhaustion or limited persistence is an obstacle. Before ACT are considered in MM, high-dose (HD) melphalan followed by autologous st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mika, Thomas, Ladigan-Badura, Swetlana, Maghnouj, Abdelouahid, Mustafa, Bakr, Klein-Scory, Susanne, Baraniskin, Alexander, Döhring, Sascha, Fuchs, Ilka, Ehl, Stephan, Hahn, Stephan A., Schroers, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759611/ https://www.ncbi.nlm.nih.gov/pubmed/33363008 http://dx.doi.org/10.3389/fonc.2020.568056

Ejemplares similares

Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells
por: Mika, Thomas, et al.
Publicado: (2020)

Liquid biopsy based HER2 amplification status in gastric cancer patients indicates clinical response
por: Klein-Scory, Susanne, et al.
Publicado: (2023)

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2020)

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
por: Althaus, Jonas, et al.
Publicado: (2023)

The value of bone marrow biopsy for staging of patients with primary CNS lymphoma
por: Margold, Michelle, et al.
Publicado: (2021)

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts
por: Reissig, Timm M., et al.
Publicado: (2023)

Quantification of cell-free DNAfor the analysis of CD19-CAR-T cells during lymphoma treatment
por: Mika, Thomas, et al.
Publicado: (2021)

Liquid biopsy can cure early colorectal cancer recurrence – Case Report
por: Baraniskin, Alexander, et al.
Publicado: (2023)

Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report
por: Nilius-Eliliwi, Verena, et al.
Publicado: (2021)

Activation leads to a significant shift in the intracellular redox homeostasis of neutrophil-like cells
por: Xie, Kaibo, et al.
Publicado: (2019)

Disabling VEGF-Response of Purkinje Cells by Downregulation of KDR via miRNA-204-5p
por: Gehmeyr, Julian, et al.
Publicado: (2021)

Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2018)

In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging
por: Yosef, Hesham K., et al.
Publicado: (2015)

Keratin23 (KRT23) Knockdown Decreases Proliferation and Affects the DNA Damage Response of Colon Cancer Cells
por: Birkenkamp-Demtröder, Karin, et al.
Publicado: (2013)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3ε
por: Liffers, Sven-T, et al.
Publicado: (2011)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.
por: Pritchard, J., et al.
Publicado: (1982)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Melphalan Culprit or Confounder in Acute Encephalopathy during Autologous Hematopoietic Stem Cell Transplantation?
por: Alayón-Laguer, Diógenes, et al.
Publicado: (2012)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

Case Report: Hemophagocytic Lymphohistiocytosis and Non-Tuberculous Mycobacteriosis Caused by a Novel GATA2 Variant
por: Mika, Thomas, et al.
Publicado: (2021)

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
por: Mika, Thomas, et al.
Publicado: (2019)

Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL
por: Baraniskin, Alexander, et al.
Publicado: (2021)

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies
por: Kast, Florian, et al.
Publicado: (2021)

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan
por: Nieto, Yago, et al.
Publicado: (2017)

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
por: Frankiewicz, Andrzej, et al.
Publicado: (2018)

Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis
por: Hoshino, Junichi, et al.
Publicado: (2008)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning
por: Ursu, Sorana G., et al.
Publicado: (2023)

Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
por: Weißert, Kristoffer, et al.
Publicado: (2022)

Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2017)

Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant
por: Cho, Yu Kyoung, et al.
Publicado: (2018)

Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML
por: Gurevich, Ekaterina, et al.
Publicado: (2022)

PB2193: IS HYPERHYDRATION NECESSARY FOR HIGH DOSE MELPHALAN CONDITIONING REGIMEN IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Mora Argumánez, M., et al.
Publicado: (2022)

Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation
por: Martino, Massimo, et al.
Publicado: (2023)

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
por: Zulian, G. B., et al.
Publicado: (1989)

Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
por: Cornbleet, M. A., et al.
Publicado: (1983)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_328nrmk9ehhh5qpjn6o6o5ebfa